DDAH I Antibody (C-4): sc-271337

DDAH I Antibody (C-4) is a mouse monoclonal IgG1 antibody that detects DDAH I in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). DDAH I, a member of the dimethylarginine dimethylaminohydrolase family, plays a crucial role in regulating nitric oxide production by hydrolyzing dimethylarginine (ADMA) and monomethyl arginine (MMA), both of which are known inhibitors of nitric oxide synthases. The proper functioning of DDAH I is vital for maintaining vascular health, as impairment can lead to ADMA accumulation, resulting in reduced cyclic guanosine monophosphate (cGMP) levels and subsequent cardiovascular complications. Notably, DDAH I is predominantly expressed in endothelial cells, where DDAH I facilitates nitric oxide synthesis induction, particularly in response to all-trans-retinoic acid (atRA). This regulation of nitric oxide is essential for various physiological processes, including vasodilation and blood flow regulation, highlighting DDAH I′s importance in cardiovascular homeostasis. Anti-DDAH I antibody (C-4) is highly valuable for researchers studying nitric oxide signaling pathways and their implications in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DDAH I Antibody (C-4) References:

1. Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy.  |  Wetzel, MD., et al. 2020. Am J Physiol Renal Physiol. 318: F509-F517. PMID: 31904280
2. DDAH-1, via regulation of ADMA levels, protects against ischemia-induced blood-brain barrier leakage.  |  Zhao, Y., et al. 2021. Lab Invest. 101: 808-823. PMID: 33574439
3. DDAH1/ADMA Regulates Adiponectin Resistance in Cerebral Ischemia via the ROS/FOXO1/APR1 Pathway.  |  Zhao, Y., et al. 2022. Oxid Med Cell Longev. 2022: 2350857. PMID: 35509834
4. DDAH1 Protects against Acetaminophen-Induced Liver Hepatoxicity in Mice.  |  Shen, X., et al. 2022. Antioxidants (Basel). 11: PMID: 35624743
5. Metabolite asymmetric dimethylarginine (ADMA) functions as a destabilization enhancer of SOX9 mediated by DDAH1 in osteoarthritis.  |  Wu, Y., et al. 2023. Sci Adv. 9: eade5584. PMID: 36753544
6. Hepatic DDAH1 mitigates hepatic steatosis and insulin resistance in obese mice: Involvement of reduced S100A11 expression.  |  Shen, X., et al. 2023. Acta Pharm Sin B. 13: 3352-3364. PMID: 37655336
7. DDAH1 Protects against Cardiotoxin-Induced Muscle Injury and Regeneration.  |  Feng, F., et al. 2023. Antioxidants (Basel). 12: PMID: 37760057
8. DDAH1 recruits peroxiredoxin 1 and sulfiredoxin 1 to preserve its activity and regulate intracellular redox homeostasis.  |  Yuan, J., et al. 2024. Redox Biol. 70: 103080. PMID: 38354630
9. DDAH1 promotes neurogenesis and neural repair in cerebral ischemia.  |  Gao, Q., et al. 2024. Acta Pharm Sin B. 14: 2097-2118. PMID: 38799640
10. DDAH-1 maintains endoplasmic reticulum-mitochondria contacts and protects dopaminergic neurons in Parkinson's disease.  |  Zhao, Y., et al. 2024. Cell Death Dis. 15: 399. PMID: 38849335

The preferred DDAH I antibody is DDAH I Antibody (D-6): sc-514841.